Research Paper Volume 13, Issue 1 pp 450—459

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis

Forest plots comparing OS and ORR for talazoparib, olaparib, and TPC. (A) OS; (B) ORR.

Figure 5. Forest plots comparing OS and ORR for talazoparib, olaparib, and TPC. (A) OS; (B) ORR.